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The sweet taste in humans is mediated by the TAS1R2/TAS1R3 G
protein-coupled receptor (GPCR), which belongs to the class C family
that also includes the metabotropic glutamate and γ-aminobutyric
acid receptors. We report here the predicted 3D structure of the full-
length TAS1R2/TAS1R3 heterodimer, including the Venus Flytrap
Domains (VFDs) [in the closed–open (co) active conformation], the
cysteine-rich domains (CRDs), and the transmembrane domains
(TMDs) at the TM56/TM56 interface. We observe that binding
of agonists to VFD2 of TAS1R2 leads to major conformational
changes to form a TM6/TM6 interface between TMDs of TAS1R2
and TAS1R3, which is consistent with the activation process ob-
served biophysically on the metabotropic glutamate receptor 2
homodimer. We find that the initial effect of the agonist is to pull
the bottom part of VFD3/TAS1R3 toward the bottom part of VFD2/
TAS1R2 by ∼6 Å and that these changes get transmitted from
VFD2 of TAS1R2 (where agonists bind) through the VFD3 and the
CRD3 to the TMD3 of TAS1R3 (which couples to the G protein). These
structural transformations provide a detailed atomistic mechanism
for the activation process in GPCR, providing insights and structural
details that can now be validated through mutation experiments.
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Gprotein-coupled receptors (GPCRs) play an essential signalingfunction throughout all eukaryote systems, serving as the basis
for detecting light, smell, nociceptive signaling, and taste along with
dopamine, serotonin, adrenaline, etc. (1). Generally, binding of a
signaling ligand to the exterior of a cell causes a G protein at the
intracellular interface to dissociate, which then triggers a sequence of
events that respond to the signal. There are now structures for ∼32
human GPCRs, including 4 that have been activated (2); however, a
detailed understanding of the activation mechanisms of monomeric
GPCRs is still lacking (3). This is most unfortunate because about
half the drugs under development involve GPCRs and it is most
important to know whether the drug will serve as an agonist to ac-
tivate the G protein or as an antagonist or inverse agonist.
Particularly interesting here are the class C GPCRs, which in
addition to a seven-helix transmembrane domain (TMD) include
a large N-terminal segment consisting of a Venus Flytrap Domain
(VFD) and a cysteine-rich domain (CRD). Biophysical measure-
ments on the class C glutamate dimer receptor 2 (mGluR2) have
shown that the inactive or resting state (R) dimer interface in-
volves contacts between TMs 4 and 5 of each TMD, whereas
formation of the fully active state is associated with motions in
which the extracellular (EC) projections of the two TM6s move
together to form a TM6–TM6 interface (4).
In addition, biophysical experiments on the class C sweet receptor,
consisting of the TAS1R2/TAS1R3 heterodimer, indicate that su-
crose and glucose bind to the VFD of both the TAS1R2 and
TAS1R3 subunits (5, 6), whereas other sweeteners, such as aspar-
tame and stevioside (Stev), interact only with the VFD2 (VFD of
TAS1R2) subunit (7–9). Moreover, the allosteric binding site at the
TMD3 (TMD of TAS1R3) interacts with modulators of the receptor
function, such as lactisole (9, 10). Particularly interesting is that for
most sweeteners binding to the VFD2 causes activation of the G
protein at the intracellular region of the TMD3.
We report here dynamical studies on binding of agonists to the
class C GPCR TAS1R2/TAS1R3 heterodimer (11), in which we
observe that binding of an agonist to VFD2 leads to the motions of
the EC projections of the two TM6s together, just as observed
experimentally for mGluR2, and we observed that the dynamics
involves a coupling through VFT3 through CRD3 to TMD3, which
is consistent with experiments on the sweet receptor. This is an
atomistic dynamical study connecting the binding of agonist to the
EC surface with the changes in the TMD of GPCR.
Because there are no full heterodimer models available from
either experiment or theory to explain how binding of sweetener to
VFD2 elicits activation by the intracellular region for TMD3, we
constructed a detailed atomistic structural model of the full sweet
taste receptor heterodimer (a total of 1,598 residues) comprising
all three domains: VFDs, CRDs, and TMDs. This involves three
steps (see Materials and Methods and SI Appendix for details).
A: Prediction of the TMD Dimer for TAS1R2 and TAS1R3 and the
Allosteric Modulator Binding Sites.
A1) We predicted the ensemble of 25 stable structures for the
TMD of all TAS1R1s, -2s, and -3s. Because there is no crystal
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structure for the sweet receptor, we used our GEnSeMBLE
Complete Sampling Hierarchical Scoring (CoS-HS) technique
(12). This has been successful at predicting the 3D struc-
tures of other GPCRs [such as chemokine CCR5 (13) and
cannabinoid CB1 (14)].
A2) We provided some validation of these TMD structures by
predicting the binding pose of allosteric modulators to
TMD2 and also TMD1.
A3) We next constructed the TMD heterodimer for TM45/
TM45 and TM56/TM56 interfaces based on GPCR dimers
from recent crystal structures of class A mu opioid receptor
[OPRM; Protein Data Bank (PDB) ID code 4DKL] (15)
and β1 adrenergic receptor (β1AR) (16).
B: Prediction of the VFD Dimer for TAS1R2 and TAS1R3 and the
Agonist Binding Sites.
B1) We first constructed structures for the VFD/CRD based on
homology to the X-ray structures for the VFD dimer of the
metabotropic glutamate receptor (mGluR) 1, 3, and 5 using
the closed–open (co) structure for the VFD dimer appro-
priate for the active (A) form (17). We then annealed this
full VFD dimer in water with appropriate ions.
B2) We provided some validation of these structures by predict-
ing the binding pose of agonists (sucrose and Stev) bound to
the VFD2. To examine the activation by other agonists, we
matched nine with known sweeteners to the same binding
site and annealed their structures.
C: Coupling VFD/CRD Dimer with TMD Dimer to Obtain Full TAS1R2
and TAS1R3 Heterodimer.
C1) We positioned the VFDs/CRDs on top of the TMD heter-
odimer and coupled the bonds to construct the full-length
heterodimer receptor. Then, we immersed the full hetero-
dimer into a periodic POPC membrane containing a water
box with appropriate ions (total of 192,000 atoms per
periodic box).
C2) Next we carried out 20 ns of molecular dynamics (MD) at
310 K for the 11 cases—10 agonists and the apo-protein—
to examine the processes related to activation.
C3) To probe the details of how information on binding of
agonist to VFD2 gets transmitted to TMD3 and then acti-
vation, we carried out a series of constrained MD.
In step C2, we found that the agonist and the allosteric mod-
ulator-bound complexes lead to major conformational changes in
the VFD3, CRD3, and TMD3 that evolve the TMD2/TMD3 in-
terface from TM56/TM56 coupling of the co active (coA) form to
a structure in which the upper parts of the TM6 helices form a
TM6/TM6 interface. This result is consistent with biophysical
measurements on the class C mGluR 2, where the TMD dimer
interacting at the TM45/TM45 interface is associated with the
resting or relaxed (R) state, whereas the TMD dimer interacting at
the TM56/TM56 interface is associated with the A state, which
upon activation by agonist leads to the TMD dimer migrating
to a configuration in which the TMD interacts at the TM6/TM6
interface (4). Our MD simulations of the agonist-induced
transformation of the TAS1R2/TAS1R3 sweet taste heter-
odimer lead to exactly the same transformations observed
experimentally for the mGluR2 homodimer, representing an
atomistic simulation that follows the GPCR dimer activa-
tion process. In contrast, the apo-dimer does not undergo this
transformation.
Results
Step A: GEnSeMBLE Predictions of the Structures for the Seven-Helix
TMD Bundles for All Three TASRs of Family 1.
Step A1) SI Appendix, Fig. S1 shows the TMD regions and multi-
ple sequence alignments with their homology templates
of human mGluR1 and mGluR5 (SI Appendix, Fig. S1).
The conserved residues in each TMD (×.50) in class C
GPCRs match with the same position (N1.50, D2.50,
R3.50 in D/ERY; W4.50, P5.50, P6.50 in FxxWxY; and
P7.50 in NPxxY motif) as class A GPCRs:
1.50: L581 at TAS1R1, T580 at TAS1R2, and V583 at
TAS1R3;
2.50: all L at TAS1Rs (L612 at TAS1R1, L611 at TAS1R2,
and L614 at TAS1R3);
3.50: L656 at TAS1R1, I655 at TAS1R2, and I658 at TAS1R3;
4.50: S687 at TAS1R1, T686 at TAS1R2, and M688 at
TAS1R3;
5.50: all Ls at TAS1Rs (L738 at TAS1R1, L738 at TAS1R2,
and L740 at TAS1R3);
6.50: A775 at TAS1R1, S775 at TAS1R2, and S777 at
TAS1R3; and
7.50: F804 at TAS1R1, S804 at TAS1R2, and L806 at TAS1R3.
The templates for the initial positions of the seven helices and the
shapes of the helices were based on the X-ray structures of human
mGluR1 (PDB ID code 4OR2) (18) and mGluR5 (PDB ID code
4OO9) (19), which are class C GPCRs with sequence identities of
17–25% to our two targets. As discussed in SI Appendix, we selected
the most stable packing for the TMD of TAS1R1, TAS1R2, and
TAS1R3, denoted as TMD1, TMD2, and TMD3.
We found a very stable salt bridge between D735 (5.47) and
K689 (4.53) in the EC binding site for the allosteric agonist in
TAS1R2. Other stable salt bridges in the cytoplasmic end involve
(a) R651 (3.46), E758 (6.33), and K811 (7.57) among TM3, -6,
and -7 in TAS1R2; (b) E751 (5.63) and K660 (3.55) between
TM3–5 in TAS1R2; and (c) E657 (3.49) and R677 (4.40) be-
tween TM3 and -4 in TAS1R3.
For all TAS1Rs we find:
• the conserved disulfide bridge between C3.25 in TM3 and
EC2 that is observed in most class A GPCRs, and
• the conserved ionic lock between R3.50 and E6.30 in the
D/ERY motif of class A GPCRs is replaced with the alterna-
tive salt-bridge interaction between conserved R/K3.46 and
E6.33 at the cytoplasmic end in class C GPCRs. However,
for TAS1R3, the corresponding residues are Q3.46 and R6.33,
leading to an H bonding, not a salt bridge.
These observations show that our structures are consistent
with previously known signatures of the broader GPCR super-
family as well as the class C subfamily.
Step A2) As the first validation of the predicted structures for
the seven-helix TMD (SI Appendix, Fig. S2), we used
DarwinDock (13) to predict the binding site for the
allosteric ligands to each TAS1R TMD, with the
results presented in SI Appendix, Table S10. See SI
Appendix for details. Here, S819 [1-((1H-pyrrol-2-yl)
methyl)-3-(4-isopropoxyphenyl)thiourea] is a sweet
compound that interacts with TMD2 (20), and Lactisole
is a competitive inhibitor of the sweet taste receptor that
binds to TMD3 (TMD of TAS1R3) (9, 21).
Step A3) To generate a starting structure for the TMD hetero-
dimer between TAS1R2 and TAS1R3, we used struc-
tural insights about GPCR dimerization from recent
crystal structures of class A OPRM (PDB ID code
4DKL) (15), kappa opioid receptor (OPRK) (22),
and β1AR (16). These crystal structures consist of a
parallel, symmetric dimer with symmetric dimeric in-
terfaces (see more details in SI Appendix).
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We conclude that only the TM45/TM45 or TM56/TM56
models are realistic. This is supported by the observation that
TM5 and TM6 are involved in the ligand binding pocket, which
might facilitate coupling of the TM5 and TM6 in one monomer
through the TM56/TM56 contacts to the other monomer to af-
fect ligand binding or signaling properties.
Step B: Predicted Structure for the VFD Dimer of TAS1R2/ TAS1R3.
Step B1) X-ray structures of the VFD without the TMD have
been obtained for the mGluR class C GPCRs in several
conformations with and without bound agonists and
antagonists (23). These results have been interpreted
in terms of two configurations for each VFD: the o state
and c state.
For the VFD heterodimer, the “oo” state of the VFD dimer is
considered to be inactive or resting (ooR), and the “co” and “cc”
states are considered to be active (coA or ccA). We used the
mGluR X-ray data to generate models of the oo and co confor-
mations for the VFD dimer of TAS1R2 and TAS1R3 heterodimer.
Using the rat mGluR1 coA structure (PDB ID code 1ewk)
(17), we generated a homology model of the co56 VFD heter-
odimer of TAS1R2/1R3 heterodimer (SI Appendix, Fig. S3,
Center). We consider this to provide a realistic dimer packing for
the co VFD.
Step B2) We first used DarwinDock (13) to predict the binding
sites for sucrose, Stev, and MogV sweeteners binding
to VFD2 (SI Appendix, Fig. S4) and equilibrated these
structure with MD in explicit solvent. As described in
SI Appendix, the results for sucrose and Stev are in
agreement with available mutation data.
We matched in eight additional stevia or nonstevia glycoside
agonists (Table 1 and SI Appendix, Table S13) into the predicted
binding site at VFD2 and annealed them through 10 quench
anneal cycles.
We considered four Stev analogs for which experimental data
(24) are available:
• most sweet: Stev and Rebaudioside A (RebA);
• intermediate sweetness: Steviolbioside (Stbs) and Rubusoside
(Rubu); and
• least sweet: 2H-Stev.
We matched each of these with the Stev binding poses at each
time step and calculated the binding energy (SI Appendix, Table
S12). For all six cases, the binding energy leads to similar cor-
relations that distinguish two categories: more sweet versus less
sweet (2H-Stev). The pharmacophore analysis shows that the
snapshot at 8.7 ns provides the best correlation with the currently
known experimental SAR data. Thus, we selected the model at
8.7 ns for further MD study, including the full heterodimer, to
extract an understanding of the activation mechanism.
Based on our predicted best binding site for Stev, we also
predicted the binding site of the Mogroside V (MogV) nonstevia
glycoside that has an additional sugar linkage (1→6) at the R2
side of the VFD of the TAS1R2/1R3 heterodimers. MogV is
found in certain plants, such as the fruit of the gourd vine luo han
guo (Siraitia grosvenorii). Mogrosides are used in various natural
sweetener products such as Norbu sweetener and have been
investigated as possible anticancer agents (25).
We found a common binding site between MogV and Stev.
The sugar of R1 (R-COO) in Stev roughly overlaps the sugar of
R1’ (R-O) in MogV, and the sugar of R2 (R-O) in Stev and R2’
(R-OH) in MogV overlapped each other, as shown in Fig. 1 and
SI Appendix, Fig. S4.
The hydroxyl groups of MogV make strong HBs with adjacent
hydrophilic residues. The hydrophilic residues are D142, D218, and
E302 at theR1/R’ side and K65, D278, D307, and R383 at the
R2/ R2’ side. The participation of these polar residues agrees with
experiments finding that D142A and E302A abolished the activities
of Stev (26). Moreover, Ala mutations of residues S40, K65, Y103,
D142, D278, E302, P277, and R383 all diminished the response to
Stev, which is consistent with our predicted binding site (26). MogV
has an extra hydrophilic interaction at the OH group with N44.
Step C: The Full-Length TAS1R2/TAS1R3 Heterodimer Sweet Taste
Receptor and the Atomistic Mechanism of Activation.
Step C1) We combined the equilibrated VFD dimer in the co
configuration including bound agonist with the TMD
dimer in the 5/6 or A configuration including bound
S819 allosteric agonist at TMD2 to obtain a model for
the full TAS1R2/1R3 heterodimer complex bound with
or without agonists at the co VFD of TAS1R2 and
with TAS1R2.
Step C2) We inserted the predicted complexes from step C1 into a
periodically infinite lipid POPC bilayer, solvated with
40,030 water molecules, and carried out 20 ns of MD
at physiological salt concentration at 310 K (a total of
198,000 atoms) using the NAMD 2.9 (NAnoscale Molec-
ular Dynamics) program (27). The MD results for the
MogV–TAS1R2/1R3 heterodimer complex (Fig. 2) show
that the binding site of MogV remains stable through
20 ns with some minor changes in HBs at the binding
site of all flexible hydroxyl groups of the glucose ring. Thus,
R383 and K65 of the upper lobe and D278 and D307 of
the lower lobe serve as the electrostatic pincer residues to
bind the agonist. These results are consistent with the loss
in activity for D278K/K65D double mutations of the sweet
taste receptors (26). Thus, the electrostatic pincer residues
of the VFD dimer include R383 and K65 of the upper
lobe and D278 and D307 of the lower lobe.
We found stable inter- or intra-salt bridges in the TAS1R2/1R3
heterodimer complex (SI Appendix, Fig. S9). In the co upper VFD,
we observed a stable salt bridge between E145 in TAS1R2 and K155
in TAS1R3, plus a slightly stable interaction between R176 in
TAS1R2 and E148 in TAS1R3 that exhibits in most MD. In the
VFD of TAS1R2, we find intradomain salt bridges among K65,
D278, and D307 and between D307 and R383 that stabilize the c
conformation between the upper and lower ligand binding domain
of VFD2. In the CRD, we found stable inter-salt bridges between
D519 in TAS1R2 and R530 in TAS1R3 and between E751 in
TAS1R2 and R762 in TAS1R3. In the TMD, our MD simulations
identified important salt bridges between E751 (5.63) in TAS1R2
Table 1. Characteristics of activation
Name VFD2–VFD3 Dist TM6-6’ Cα No. TM6–6’ Cα
RebM 40.04 8.17 1.35
Stev 40.81 9.86 0.00
RebN 38.26 6.08 8.60
RebD 37.84 5.79 13.15
MogV 41.21 4.57 18.40
RebA 38.64 6.87 5.30
Rubu 43.08 6.56 7.40
RebE 41.18 7.58 4.00
RebC 39.04 5.94 12.00
RebG 37.36 10.84 0.00
Apo 43.01 9.23 0.2
VFD2–VFD3 is the distance between the center of the lower VFD2 and the
center of VFD3. Dist TM6-6’ is the shortest Cα distance between TM6 of
TMD2 and TM6’ of TMD3. No. TM6–6 Cα is the number of Cα partners of
TM6–TM6 with distances shorter than 9 Å. These quantities were averaged
over the period from 8 to 10 ns MD. The cases we consider outliers in our
interpretation of the binding mechanism are shaded. The outliers are dis-
played in italics. Mog, Mogroside; Reb, Rebaudioside; Rubu, Rubusoside;
Stev, Stevioside.
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(D5.63 in TAS1R1) and R762 (6.35) in TAS1R3 that stabilize the
TM5/6 interface of heterodimer complex bound with strong sweet-
eners but not with weak sweeteners such as RebC, RebG, or apo.
Our MD simulations with the co56 heterodimer model find that
agonists bound to VFD2 lead to major conformational changes in
which the TMD interaction across the heterodimer changes grad-
ually from having a TM56/TM56 interface at the beginning to
having close interactions between TM6/TM6 as shown in Fig. 3 and
SI Appendix, Fig. S10. These MD results suggest that the combi-
nation of agonist and allosteric agonist facilitates the conforma-
tional rearrangement in which the TM56/TM56 co interface evolves
to move the TM6 helices to much shorter distances, especially be-
tween the upper parts of the two TM6/TM6 helices. We also ob-
served that for the TAS1R2/1R3 heterodimer with agonist and
allosteric agonist, the salt bridges across the respective VFDs and
TMDs are stabilized compared with MD of the apo heterodimer.
We find that the TMD of TAS1R3 is highly flexible because it lacks
the ionic constraints of the TAS1R2 TMD, which has many inter-
helical salt bridges involving TM3, -6, and -7; TM5 and -6; and TM4
and -5 as shown in SI Appendix, Fig. S9.
For class C mGluR2, biophysical measurements established that
the dimer interface involving TM45/TM45 is associated with the
inactive or resting state (R), whereas formation of the TM6/TM6
interface is associated with the fully A state (4). This suggests an
intermediate state of the receptor that may exhibit a TM56/TM56
interface. Because this interface has been observed in crystal
structures of other GPCRs, we used them to build this interface to
facilitate activation. The MD with the inactive oo45 heterodimer
showed a very stable structure (SI Appendix, Fig. S11). The con-
formational rearrangement we observed in the co56 model MD, in
which the TM56/TM56 TMD interface transforms to the TM6/
TM6 interface, is consistent with biophysical studies on the mGluR2
homodimer (a class C GPCR), which find these changes to be as-
sociated with activation (4).
Our MD simulations show major conformational changes in the
lower part of VFD2 and VFD3 (Table 1 and SI Appendix, Table
S13). Here we define a geometric center for each part (SI Ap-
pendix, Fig. S12) and measure the distance across the VFD2 and
VFD3. We find that 9 out of 10 agonists lead quickly to coupling
of the bottom parts of VFD dimer to stabilize at 37–41 Å com-
pared with 43 Å for the apo protein. The exception is Rubu. These
distances can be compared with the crystal structures lacking the
TMDs (64.7 Å for ooR, 68.1 Å for ccR, 41.3 Å for ooA, and
38.7 Å for coA), where this distance in the R (resting) structure is
25 Å larger than for the A structure (SI Appendix, Fig. S13).
We also observed that 8 out of 10 agonists show rapid rear-
rangement of the TMD interface from TM56/TM56 to TM6/TM6.
Our MD simulations also show major conformational changes
at TM6 in TMD3 that bring it closer to the upper parts of the
TM6 helix from TMD2 (SI Appendix, Fig. S14). At this point in
the MD, the conformational changes in TM6 involve only the
upper part, because there is a strong inter-salt bridge constraint
between E751 (5.63) in TAS1R2 and R762 (6.35) in TAS1R3
that stabilizes the bottom part of the TM56/TM56 interface.
P6.53 is conserved in mGluRs and in TAS1R3 but not in
TAS1R1 and TAS1R2, where residue 6.53 is Thr. Thus, the high
Stevioside Mogroside V
Fig. 1. Predicted best binding modes for Stev and MogV bound to the VFD (VFD2) of the human sweet taste receptor (TAS1R2/1R3). The predicted phar-
macophore is at the bottom. The unified cavity binding components are in SI Appendix, Table S11.
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flexibility of upper TM6 of TAS1R3 is likely due to both the
weak HB network in TMD3 and the presence of Pro in the upper
TM6 of TMD3.
The conformational rearrangement of TM56/TM56 to TM6/
TM6 observed in the MD is consistent with the experiments in-
volving cysteine cross-linking at the mGluR2 TMD dimer in-
terface. Disulfide cross-linking was observed only when one amino
acid in TM4 (L698C), TM5 (Y734C), or TM6 (V782C) was
substituted for cysteine (4). The corresponding amino acids at 6.57
are A782 in TAS1R2 and N784 in TAS1R3. Our MD leads to an
intermolecular distance of 10.5 Å between the two residues at 6.57,
which we consider sufficient to allow a disulfide bridge to form.
Summarizing, the changes in the agonist-bound TAS1R2/
TAS1R3 heterodimer observed in the 10 ns of MD are mostly (8
out of 10 cases) consistent with the changes associated with ac-
tivation in the mGluR class C dimers.
Structural and biophysical studies of mGluR class C GPCRs
reported that a major rearrangement in the TMD dimer in-
terface from TM45/TM45 to TM6/TM6 (time constant, ∼35 ms)
is essential for receptor activation by agonists, revealing a key
step in mGluR activation. This change is followed by activation
of a single TMD within the dimer, in which the bottom part of
TM3 and TM6 of TAS1R3 separate so that there is room for G
protein to insert into the membrane (time constant, ∼50 ms).
Our simulations do not include the G protein, so we cannot yet
comment whether TMD3–6 separation will happen in our model.
Step C3) To learn how information is transmitted from agonist
binding at VFD2 to activation of the G protein at
TMD3, we carried out MD simulations in which particu-
lar subdomains were fixed in the MD. We carried out
10 ns MD at 310K for the MogV-bound heterodimer
(our most active agonist) with one of the domains
(CRD2, TMD2, VFD3, CRD3, or TMD3) fixed. We
consider the measures of activation to be (a) the shortest
Cα distance between the TM6 helices of TMD2 and
TMD3 and (b) total number Cα between the two TM6s
within 9 Å. As shown in Fig. 4, we observed that:
• fixing VFD3 or CRD3 completely blocked activation,
• fixing CRD2 had almost has no effect, and
• fixing TMD2 or TMD3 has intermediate effects on activation,
which is consistent with the higher flexibility and the major
change of TAS1R3 TMD at the heterodimer interface upon
activation.
Based on these constrained MD results, we hypothesize that the
agonist signal is transferred from VFD2 through VFD3 to CRD3
and finally to TMD3 to initiate activation. Thus, we conclude that
agonist-induced coupling of the lower VFD is required for acti-
vation, followed by communication of this signal through the
VFD3 and then CRD3 to impact the top part of TMD3,
particularly TM6.
Our results are consistent with mutational studies of human/
mouse chimeras of TAS1R3 paired with human TAS1R2, which
found that CRD3 plays a critical role in sensory mechanism of
the sweet receptor. Thus, the A537P mutation of TAS1R3
stopped all responses to all sweeteners, indicating that the CRD3
must couple ligand binding in VFD2 to receptor output in the
TMD3 by modulating the strength of coupling (3).
Discussion
Our predictions for the heterodimer of the TAS1R2 and
TAS1R3 led to several observations:
i) The binding sites of sucrose and Stev have strong HBs to
nearby hydrophilic residues D142 and E302, which is con-
sistent with mutation studies. We find much stronger bind-
ing for Stev than for sucrose, perhaps explaining why Stev is
210–300 times sweeter than sucrose (24).
ii) The allosteric ligands bind to the TMD of TAS1Rs (S807 at
TAS1R1, S819 at TAS1R2, lactisole at TAS1R3), with the
interactions remaining stable during the MD.
iii) Nine out of 10 agonists lead quickly to coupling the bottom parts
of VFD dimer to distances of 37–41 Å (the exception is Rubu),
whereas for apo protein these bottom parts stay 43 Å apart. This
has been observed experimentally for model mGluR VFD di-
mers not containing the TMD. It is possible that this process
converts the inactive form R to the active form A.
iv) Starting with the TM5/6 interface for the TAS1R2/
TAS1R3 heterodimer, we find (for 8 out of 10 cases) major
TM6 TM6
TM5
TM5
A
Apo MogV
B
S819 TM6TM6
Fig. 2. Side views of the 3D structure of the (A) apo- and (B) MogV-bound
TAS1R2 (red)/1R3 (blue) heterodimer. The MogV agonist is shown in VFD2 as
a yellow space-filling model, whereas the S819 agonist modulator is the
yellow structure at the EC part of TMD2. SI Appendix, Fig. S2 shows a more
detailed binding site for the S819 allosteric agonist. The yellow arrows be-
tween VFD2 and VFD3 show the separation (Å) between the geometric
center of lower VFD2 and lower VFD3 (VFD2–VFD3 in Table 1), whereas
yellow arrows between TMD2 and TMD3 show the distance (Å) between the
closest Cα of TM6/TMD2 with a Cα of TM6’/TMD3 (Dist TM6-6’ Cα in Table 1).
These numbers are in SI Appendix, Table S13 for all 11 cases.
TM6/TM6 TM56/TM56 
TM56/TM56 TM56/TM56 
1 
Extracellular view 
Cytoplasmic view 
Fig. 3. The conformational rearrangement at the TMD interface of hetero-
dimers of sweet taste receptor TAS1R2 (red)/TAS1R3 (blue) from the start (Left)
to the end (Right) after 20 ns of MD. Viewed from the EC view (Top) and the
cytoplasmic view (Bottom). The original TM56/TM56 interface changes by
moving the upper TM6 helices closer, leading to a TM6/TM6 interface mainly
at the EC side. This motion is observed experimentally for the mGlu2 homo-
dimer. The EC views for all 11 cases are shown in SI Appendix, Fig. S15.
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conformational changes in which the TM5/6 interface be-
tween the TMD dimers evolves into closer interactions
between the upper parts of the TM6 helices (the two ex-
ceptions are RebG and Stev). This result agrees well with
the biophysical measurements in the class C mGluR2 where
the TM4/5 interface is known to be associated with the in-
active state whereas the TM6 interface is associated with the
fully A state.
v) We find that fixing the atoms of either VFD3 or CRD3 pre-
vents this activation, whereas fixing CRD2 has no effect. This
indicates that the movement of the bottom half of the VFD
causes changes in the CRD3 that communicates through
CRD3 with the top part of TMD3 to induce the initial steps
in activation.
Because these structures do not include the G protein that must
be coupled at the intracellular interface to the EC motions of the
TM6 helices, we cannot yet discuss how these motions affect the G
protein activation. We hope to include such couplings in future
studies. To enable others to investigate such interactions, we in-
clude 3D coordinates of the state we consider to be activated.
Our predicted 3D structures for the TAS1R2/TAS1R3 sweet
taste receptor exhibit binding and activation profiles consistent
with biophysical experiments on other class C mGluR2 dimers.
After acceptance of our manuscript for publication, a paper
appeared (28) that developed a homology model of the sweet
taste receptor based on structures of other class C GPCRs. They
compared the key residues in ligand binding and activation with
∼600 single-point site-directed mutations. These mutations are
also in good agreement with our structure.
Most promising is that the changes known experimentally to
be associated with activation are captured in our short MD
studies. This is the first time that a class C GPCR dimer acti-
vation has been modeled with MD. In addition, these studies
capture the structural changes related to the agonist binding at
the EC VFD2 of the TAS1R2 subunit and how those changes
propagate allosterically to the TMD3 of TAS1R3 subunit, which
putatively couples to the G protein. We expect that these studies
will be useful to gain additional understanding of the activation
mechanism in both the TAS1R family and other class C GPCR
dimers, including the mGluR and γ-aminobutyric acid (GABA)
receptors. These structures and models provide the basis for
experimental studies aimed at probing the important molecular
interactions controlling activation.
Materials and Methods
We used our GEnSeMBLE CoS-HS technique (12) to generate the TMD of
all TAS1Rs.
We used DarwinDock (13) to predict the binding site for the allosteric
ligands to each TAS1R TMD as well as the sweeteners to each TAS1R2 VFD.
We used theNAMD2.9 (NAnoscaleMolecular Dynamics) program (27) to rub
MD for the TAS1R2/1R3 heterodimer complex bound with various sweeteners.
See SI Appendix for method details.
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Fixed CRD3
Fixed VFD3
Fixed TMD3
Fixed TMD2
Fixed CRD2
No Fix
Not acve
Fully acve
Fig. 4. Trajectory analysis of the shortest Cα distance (Å) between TM6 of
TAS1R2 and TAS1R3 TMD after 10 ns of MD. We see that the fix CRD2 case is
the same as no fix, indicating no effect on activation, whereas the fix-VFD3
and fix-CRD3 cases show no activation (similar to apo protein) The fix-TMD2
and fix-TMD3 cases are intermediate. The total number of Cα between the
two TM6s within 9 Å is shown in SI Appendix, Fig. S16.
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